Novartis’ oral Fabhalta (iptacopan) has been approved by the US Food and Drug Administration (FDA) as the first treatment for ...

CKD is responsible for chronic inflammation and oxidative stress and results in the build-up of uremic toxins, which ...

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting ...

Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 on evaluation and management of chronic kidney disease (CKD) in ...

Lipid abnormalities are a common complication in diabetic kidney disease (DKD), contributing to disease progression and ...

Chronic kidney disease (CKD) is defined as a progressive ... measured by the level of proteinuria – and the decline in glomerular filtration rate. The most severe form is end-stage renal disease.

A new Canadian study has found that chronic kidney disease (CKD) is linked to lower cognitive performance, affecting ...